Boehringer Ingelheim’s large-scale manufacturing facility in Germany and Rentschler’s medium-scale plant are part of the agreement.

Rentschler Biotechnologie and Boehringer Ingelheim inked a preferred partnership agreement that allows their respective clients to use the other’s facilities. Rentschler’s clients will have access to Boehringer Ingelheim’s large-scale mammalian biopharmaceutical production plants in Biberach, Germany. Also, Boehringer Ingelheim’s clients will be able to use Rentschler’s facilities for process development and intermediate-scale clinical supply production.

The firms believe that companies will benefit from the combined development and manufacturing know-how and facilities, leading to increased flexibility and ultimately more customized services.

Rentschler Biotechnologie is a CMO focused on process development and small-to-medium scale production of mammalian cell-derived biopharmaceuticals. The company currently operates eight independent GMP lines with fermentor volumes of up to 500 L. A 2,500 L fermentor was recently qualified as well, according to the firm.

Boehringer Ingelheim offers similar services with technologies optimized for large-scale industrial production. The company runs one of the largest biotech facilities with fermenter volumes of up to 15,000 L.

Previous articleDaiichi Sankyo Intends to Purchase U3 Pharma for Roughly $236M